The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 1,201–1,264 of 1,264
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
Su, W., Mukherjee, R., Yaeger, R. D., Son, J., Xu, J., Na, N., Timaul, N. M., Hechtman, J. F., Paroder, V., Lin, M., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.034 · Cited by 27
Self-citationGrivas, P. D., Grande, E., Davis, I. D., Moon, H. H., Grimm, M., Gupta, S., Barthélémy, P., Thibault, C., Guenther, S., Hanson, S., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102050 · Cited by 27
Moshitch-Moshkovitz, S., Tsarfaty, G., Kaufman, D. W., Stein, G. Y., Shichrur, K., Solomon, E., Sigler, R. H., Resau, J. H., Woude, G. F. V., & Tsarfaty, I. (2006) · Neoplasia · doi:10.1593/neo.05634 · Cited by 26
Jackson, M. R., Bavelaar, B. M., Waghorn, P. A., Gill, M. R., El-Sagheer, A. H., Brown, T., Tarsounas, M., & Vallis, K. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3594 · Cited by 26
Brinkmann, K., Ng, A. P., de Graaf, C. A., & Strasser, A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00987-0 · Cited by 26
Gandhy, S. U., Casak, S. J., Mushti, S. L., Cheng, J., Subramaniam, S., Zhao, H., Zhao, M., Bi, Y., Liu, G., Fan, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1042 · Cited by 25
Diagnostic RAS mutation analysis by polymerase chain reaction (PCR)
Cree, I. A. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2016.05.001 · Cited by 25
Zhao, S., Wu, W., Jiang, H., Ma, L., Pan, C., Jin, C., Mo, J., Wang, L., & Wang, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731527 · Cited by 25
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
Massey, A. J., Stephens, P., Rawlinson, R., McGurk, L., Plummer, R., & Curtin, N. J. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.004 · Cited by 24
Qin, H., Lu, Y., Du, L., Shi, J., Yin, H., Jiang, B., Chen, W., Diao, W., Ding, M., Cao, W., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02467-4 · Cited by 24
Kubo, T., Kawano, Y., Himuro, N., Sugita, S., Sato, Y., Ishikawa, K., Takada, K., Murase, K., Miyanishi, K., Sato, T., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0557-1 · Cited by 23
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 23
Differentiation therapy: Unlocking phenotypic plasticity of hepatocellular carcinoma
Zheng, S., Bian, H., Li, J., Shen, Y., Yang, Y., & Hu, W. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103854 · Cited by 23
Mechanisms and effects of NLRP3 in digestive cancers
Si, Y., Liu, L., & Fan, Z. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01783-6 · Cited by 23
Kim, M. S., Yamashita, K., Chae, Y. K., Tokumaru, Y., Chang, X., ZAHURAK, M. L., Osada, M., Park, H. L., Chuang, A., Califano, J. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1178 · Cited by 22
New agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 22
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More
Kostopoulos, I. V., Ntanasis‐Stathopoulos, I., Rousakis, P., Eleutherakis‐Papaiakovou, E., Panteli, C., Malandrakis, P., Angelis, N., Kanellias, N., Orologas‐Stavrou, N., Papanota, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01606 · Cited by 22
One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable
LoRusso, P. M., & Sebolt-Leopold, J. S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2026372 · Cited by 21
Talwar, G. P., Gupta, J. C., & Shankar, N. V. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01002.x · Cited by 21
Yang, M., Ramanathan, A., Glover, K., Stanley, C. B., Sanishvili, R., Chakravarthy, S., Yang, Z., Colbert, C. L., & Sinha, S. C. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01264 · Cited by 21
He, W., Huang, X., Berges, B. K., Wang, Y., An, N., Su, R., & Lu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.615889 · Cited by 21
ShP, L., Wang, Y., Huang, L., Wang, F., Zhou, J.-G., & Ma, H. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.2.391 · Cited by 20
Lakhani, N. J., Rasco, D. W., Zeng, Q., Tang, Y., Liang, Z., Wang, H., Lu, M., Chen, J., Fu, L., Wang, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3509 · Cited by 20
Liquid biopsy analysis of lipometabolic exosomes in pancreatic cancer
Guo, W., Ying, P., Ma, R., Jing, Z., Ma, G., Long, J., Li, G., & Liu, Z. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.07.006 · Cited by 20
Karashima, T., Inoue, K., Fukata, S., Iiyama, T., Kurabayashi, A., Kawada, C., & Shuin, T. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.937 · Cited by 19
Liao, X., Yuan, H., Mao, Y., Chen, N., Wang, Q., Wang, Z., Zhang, L.-D., Wang, L., Chen, S., Shi, W., et al. (2020) · Cancer Science · doi:10.1111/cas.14367 · Cited by 18
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
Raphael, J., Lefebvre, C., Allan, A. L., Helou, J. A., Boldt, G., Vandenberg, T. A., & Blanchette, P. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00770-6 · Cited by 18
Yan, P., Han, Y., Tong, A., Liu, J., Wang, X., & Liu, C. (2021) · Bioscience Reports · doi:10.1042/bsr20210866 · Cited by 18
The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia
Ghazimoradi, M. H., Karimpour-Fard, N., & Babashah, S. (2023) · Genes · doi:10.3390/genes14010131 · Cited by 18
Circulating nucleosomes as potential biomarkers for cancer diagnosis and treatment monitoring
Wang, H., Wang, Y., Zhang, D., & Li, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130005 · Cited by 18
Busch, R. A., Heneghan, A. F., Pierre, J. F., Wang, X., & Kudsk, K. A. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000871 · Cited by 17
Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity
Kelly, R. J., Darnell, C., & Rixe, O. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ff37cf · Cited by 17
Wang, Q., Liu, F., Qi, S., Qi, Z., Yan, X.-E., Wang, B., Wang, A., Wang, W., Cheng, C., Liu, X., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.003 · Cited by 17
Tumors Responsive to Autophagy-Inhibition: Identification and Biomarkers
Barbeau, L. M. O., Keulers, T. G., & Rouschop, K. M. A. (2020) · Cancers · doi:10.3390/cancers12092463 · Cited by 17
Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting
Kim, H. J. (2022) · Medicina · doi:10.3390/medicina58050649 · Cited by 17
Sepporta, M.-V., Praz, V., Balmas Bourloud, K., Joseph, J.-M., Jauquier, N., Riggi, N., Nardou-Auderset, K., Petit, A., Scoazec, J.-Y., Sartelet, H., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02958-6 · Cited by 16
Chen, T., Tang, X., Tang, X., Feng, F., Xu, C., Zhao, Q., Wu, Y., Sun, H., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115828 · Cited by 16
Bieging-Rolett, K. T., & Attardi, L. D. (2015) · Nature · doi:10.1038/nature14374 · Cited by 15
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
Karp, J. E., & Lancet (2008) · Biologics · doi:10.2147/btt.s3485 · Cited by 15
Fuchß, T., Grädler, U., Schiemann, K., Kühn, D., Kubas, H., Dahmen, H., Zimmermann, A., Zenke, F. T., & Blaukat, A. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3500 · Cited by 15
Targeting Oncogenic RAS Protein
Longo, D. L., & Rosen, N. X. (2022) · New England Journal of Medicine · doi:10.1056/nejme2206831 · Cited by 15
Zhang, D., Hou, W., Liu, F., Yin, J., Lu, W., Li, M., Zheng, T., Lu, F., Bao, Y., & Jia, W. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0176 · Cited by 14
Zhang, M., Dong, X., Zhang, D., Chen, X., & Zhu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13891 · Cited by 14
p53: not just a tumor suppressor
Oren, M. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz070 · Cited by 14
KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma
Gallina, F. T., Marinelli, D., Melis, E., Forcella, D., Tajè, R., Buglioni, S., Visca, P., Torchia, A., Cecere, F. L., Botticelli, A., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107254 · Cited by 14
Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells
Beiner, M. E., Niv, H., Haklai, R., Elad‐Sfadia, G., Kloog, Y., & Ben‐Baruch, G. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200602001-00032 · Cited by 13
Tutar, N., Yetkin, N. A., Yazıcı, C., Önal, Ö., Kontaş, O., & KELEŞTİMUR, F. (2019) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1810-147 · Cited by 13
Jiang, L., Duan, B., Huang, J., Jiao, X., Zhu, X.-W., Sheng, H., Gao, H., & Yu, H. (2014) · PubMed · Cited by 12
Liu, D., & Zhou, K. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.005 · Cited by 12
Lim, B., Yoo, D., Chun, Y., Go, A., Cho, K., Choi, D., Jung, M. E., Lee, H. Y., Boohaker, R. J., Lee, J. S., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00664-y · Cited by 12
Li, C., Yang, X., Luo, Y., Liu, H., Zhong, X. Z., Zhou, X., Zeng, T., Tao, L., Zhou, Y., Gou, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01711 · Cited by 11
Self-citationHung, M., Wang, W.-P., & Chi, Y. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00862-y · Cited by 11
Stärkel, P., Charette, N., Borbath, I., Schneider‐Merck, T., Saeger, C. D., Abarca, J., Leclercq, I. A., & Horsmans, Y. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20849 · Cited by 10
Zhang, C., Zhang, J., Ma, Y., Zhe, H., Zhao, R., & Wang, Y. (2019) · Disease Markers · doi:10.1155/2019/1601072 · Cited by 10
Zhou, X., Tan, Y., Gou, K., Tao, L., Luo, Y., Zhou, Y., Zuo, Z., Sun, Q., Luo, Y., & Zhao, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105159 · Cited by 10
Self-citationOpportunities and challenges of next-generation DNA sequencing for breast units
Pilgrim, S. M., Pain, S. J., & Tischkowitz, M. D. (2014) · British journal of surgery · doi:10.1002/bjs.9458 · Cited by 9
Hu, W., Wang, L., Luo, J., Zhang, J., & Li, N. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s434973 · Cited by 9
Interfering Effect of Black Tea Consumption on Diagnosis of Pancreatic Cancer by CA 19-9
AL‐Janabi, A. A. H. S., & Tawfeeq, E. F. (2016) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9855-z · Cited by 8
Lactate dehydrogenase as promising marker for prognosis of brain metastasis
Pei, Y., Zhang, Y., Liu, Z., He, Y., Yu, J., Zhang, R.-J., Wang, J., Peng, X., & Fang, F. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04070-z · Cited by 8
Self-citationZeitelhofer, M., Li, H., Adzemovic, M. Z., Nilsson, I., Muhl, L., Scott, A. M., & Eriksson, U. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200649 · Cited by 7
Zhang, C., Liu, J., Chao, F., Wang, S., Li, D., Han, D., Xu, Z., Xu, G., & Chen, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742354 · Cited by 6
Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma
Soleimani, M., Nappi, L., & Kollmannsberger, C. (2020) · Future Oncology · doi:10.2217/fon-2020-0586 · Cited by 5
Wood, A. C., Zhang, Y., Mo, Q., Cen, L., Fontaine, J. P., Hoffe, S. E., Frakes, J. M., Dineen, S. P., Pimiento, J. M., Walko, C. M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac018 · Cited by 5
Self-citationWang, K., Xiang, Y., Yu, H., Cheng, Y., Feng, J.-K., Liu, Z., Shan, Y., Zheng, Y., Ni, Q., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11485-y · Cited by 4
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.